CDE Catalog

***Please contact the NINDS CDE Team (NINDSCDE@emmes.com) if you encounter any search difficulties.***

The CDE Catalog is a directory of the available NINDS CDEs. Users can search the Catalog to isolate a subset of the CDEs (e.g., all stroke-specific CDEs, etc.), and to view and download details about the CDEs.

Select any filter below to search the CDE Catalog.

For best results, clear form between searches. In addition, when specifying NeuroRehab, Sport-Related Concussion (SRC) or Traumatic Brain Injury (TBI) as the Disease, please select a Subdisease as well.

NeuroRehab Comprehensive includes all NeuroRehab CDE recommendations. NeuroRehab General includes all NeuroRehab CDE recommendations that are not disease specific. All other NeuroRehab Subdiseases include recommendations specific to existing NINDS CDE project disorders.

Choose your Time Frame for your SRC study (Acute (time of injury until 72 hours), Subacute (after 72 hours to 3 months), and Persistent/Chronic (3 months and greater post-concussion) or Comprehensive if your study falls across the study time frames.

Choose your type of TBI study (Acute Hospitalized, Concussion/Mild TBI, Moderate/Severe TBI: Rehabilitation, or Epidemiology) or Comprehensive if your study falls outside of the study types or incorporates aspects of more than one type of study.

Search Form

Displaying 701 - 725 of 1067
Operations
Selected 25 rows in this page.  
The search results below can be downloaded by clicking the checkboxes on the far left side of the table. Select the header checkbox to select all CDEs listed on the first page. Then choose CDE Detailed Report from the Choose an operation dropdown menu.
CDE ID CDE Name Definition Classification CRF Name Copyrighted or trademarked Disease Name Subdisease Name
C12239 Electron microscopy performed indicator

Indicator of whether electron microscopy was performed

Supplemental Muscle Biopsy and Autopsy Tissue Myasthenia Gravis Myasthenia Gravis (MG)
C12273 Biopsy and autopsy normal immunoreactivity assay name

Name of the normal immunoreactivity assay used

Supplemental Muscle Biopsy and Autopsy Tissue Myasthenia Gravis Myasthenia Gravis (MG)
C12521 Specimen type 2 fiber muscle biopsy percent result number

Result for type 2 fiber muscle biopsy percent

Supplemental Muscle Biopsy and Autopsy Tissue Myasthenia Gravis Myasthenia Gravis (MG)
C12531 Biopsy autopsy excessive glycogen severity result

Severe glycogen storage pathology involves excess PAS+ material that is easily identifiable on light microscopy and is evident on other stains including H and E. Mild glycogen storage pathology is difficult to determine at the light microscopic level and may only be evident on PAS stain or electron microscopy

Supplemental Muscle Biopsy and Autopsy Tissue Myasthenia Gravis Myasthenia Gravis (MG)
C12248 Pathologist name

Name of pathologist who diagnosed the case

Supplemental Muscle Biopsy and Autopsy Tissue Myasthenia Gravis Myasthenia Gravis (MG)
C17905 Biopsy and autopsy abnormal storage material text

Text describing biopsy or autopsy material that has been stored abnormally

Supplemental Muscle Biopsy and Autopsy Tissue Myasthenia Gravis Myasthenia Gravis (MG)
C12257 Biopsy and autopsy nemaline rod type

Rod-shaped structures, visible at high magnification, which are most visible on Gomori trichrome stain and on EM preparations

Supplemental Muscle Biopsy and Autopsy Tissue Myasthenia Gravis Myasthenia Gravis (MG)
C12265 Biopsy and autopsy diagnostic abnormalities severity grade

Severity of the diagnostic muscle abnormalities

Supplemental Muscle Biopsy and Autopsy Tissue Myasthenia Gravis Myasthenia Gravis (MG)
C12230 Tissue specimen collection date and time

Date (and time if applicable and known) when the tissue specimen was collected

Core Muscle Biopsy and Autopsy Tissue Myasthenia Gravis Myasthenia Gravis (MG)
C12240 Biochemical or genetic test performed indicator

Indicator of whether subsequent biochemical or genetic testing was performed

Supplemental Muscle Biopsy and Autopsy Tissue Myasthenia Gravis Myasthenia Gravis (MG)
C12274 Biopsy and autopsy reduced immunoreactivity assay name

Reduced immunoreactivity that were noted on the immunohistochemical stains

Supplemental Muscle Biopsy and Autopsy Tissue Myasthenia Gravis Myasthenia Gravis (MG)
C12524 Inflammation severity status

Severity of Inflammation muscle diagnostic abnormalities

Supplemental Muscle Biopsy and Autopsy Tissue Myasthenia Gravis Myasthenia Gravis (MG)
C17898 Laboratory director unknown indicator

Indicator of unknown laboratory director

Supplemental Muscle Biopsy and Autopsy Tissue Myasthenia Gravis Myasthenia Gravis (MG)
C12249 Biopsy and Autopsy histochemical stains diagnostic abnormalities present type

The diagnostic abnormalities present on the histochenmical stains for the participant's/subject's tissue

Supplemental Muscle Biopsy and Autopsy Tissue Myasthenia Gravis Myasthenia Gravis (MG)
C18828 Histochemical stains used other text

The free-text field related to 'Histochemical stains used type' specifying other text. Type of standard histochemical stains used on the tissue specimen

Core Muscle Biopsy and Autopsy Tissue Myasthenia Gravis Myasthenia Gravis (MG)
C12258 Biopsy and autopsy central cores type

The composition of the central cores

Supplemental Muscle Biopsy and Autopsy Tissue Myasthenia Gravis Myasthenia Gravis (MG)
C12266 Biopsy and autopsy excessive intracellular lipid severity grade

Severe lipid storage pathology involves excess Oil Red O+ material that is easily identifiable on light microscopy and is evident on other stains including H and E. Mild lipid storage pathology is difficult to determine at the light microscopic level and may only be evident on Oil Red O stain or on electron microscopy

Supplemental Muscle Biopsy and Autopsy Tissue Myasthenia Gravis Myasthenia Gravis (MG)
C12690 Gene name

Name of the gene analyzed

Supplemental Mutation Analysis Myasthenia Gravis Myasthenia Gravis (MG)
C12789 Gene deletions duplications limits clearly defined indicator

Indicator of whether the limits of deletions and duplications are defined

Supplemental Mutation Analysis Myasthenia Gravis Myasthenia Gravis (MG)
C12797 Gene targeted variant mutational analysis type

Type of targeted variant or mutational analysis performed for the gene

Supplemental Mutation Analysis Myasthenia Gravis Myasthenia Gravis (MG)
C12806 Gene protein variant mutation name

Name using the Human Genome Organisation (HUGO) variant or mutation nomenclature of the protein variant or mutation

Supplemental Mutation Analysis Myasthenia Gravis Myasthenia Gravis (MG)
C17893 Gene missense nonsense variant point mutation location other text

The free-text field about missense/nonsense variant or point mutation at locations other than the exon and intron

Supplemental Mutation Analysis Myasthenia Gravis Myasthenia Gravis (MG)
C12782 Gene additional variants unknown significance indicator

Indicator of whether there are additional variants in other genes of unknown significance

Supplemental Mutation Analysis Myasthenia Gravis Myasthenia Gravis (MG)
C12790 Gene exon first deleted duplicated name

Name of the first exon deleted or duplicated

Supplemental Mutation Analysis Myasthenia Gravis Myasthenia Gravis (MG)
C12798 Gene missense nonsense variant point mutation location type

Type of location of the missense/nonsense variant or point mutation

Supplemental Mutation Analysis Myasthenia Gravis Myasthenia Gravis (MG)
Displaying 701 - 725 of 1067

The NINDS CDE Team does not post proprietary instruments/scales recommended by the CDE Working Groups on this website. This includes, but is not limited to, copyrighted or trademarked instruments/scales. Information about recommended instruments can be found in the Notice of Copyright (NOC) documents under ‘CRF Module/Guideline’ on each disorder’s data standards page. For any questions regarding these instruments/scales please contact the corresponding owner/author. The NINDS CDE Team is not responsible for the availability or content of these external sites, nor does the NINDS CDE Team endorse, warrant or guarantee the products, services or information described or offered at these other internet sites.